Back to Search
JACOB RYALL, MD
MD
Anesthesiology Physician
NPI: 1639750532Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Anesthesiology PhysicianPrimary
Anesthesiology
Code: 207L00000X
125079226(IL)
Research & Publications (20)
Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice.
PMID 19204053·J Physiol·2009
7-preclinical
AMPK-independent pathways regulate skeletal muscle fatty acid oxidation.
PMID 18845612·J Physiol·2008
7-preclinical
The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting.
PMID 18834902·Pharmacol Ther·2008
6-review
Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.
PMID 18567600·Exp Physiol·2008
7-preclinical
Anabolic agents for improving muscle regeneration and function after injury.
PMID 18498534·Clin Exp Pharmacol Physiol·2008
6-review
Intramuscular beta2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury.
PMID 18436698·J Appl Physiol (1985)·2008
7-preclinical
Chronic beta2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity.
PMID 18408128·Am J Physiol Heart Circ Physiol·2008
7-preclinical
Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.
PMID 18391178·Physiol Rev·2008
6-review
The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle.
PMID 18325999·Endocrinology·2008
7-preclinical
Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness.
PMID 18299960·Biogerontology·2008
6-review
Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.
PMID 17823291·Am J Pathol·2007
7-preclinical
Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia.
PMID 17702871·J Gerontol A Biol Sci Med Sci·2007
7-preclinical
Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
PMID 17134898·Neuromuscul Disord·2007
7-preclinical
The orphan nuclear receptor, NOR-1, is a target of beta-adrenergic signaling in skeletal muscle.
PMID 16901967·Endocrinology·2006
7-preclinical
Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
PMID 16621899·Am J Physiol Endocrinol Metab·2006
7-preclinical
Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
PMID 16432501·Br J Pharmacol·2006
4-observational
Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density.
PMID 15734875·Am J Physiol Heart Circ Physiol·2005
7-preclinical
Beta2-agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscle.
PMID 15479951·Am J Physiol Endocrinol Metab·2005
7-preclinical
Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.
PMID 14617677·J Physiol·2004
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 251 E HURON ST
CHICAGO, IL 60611 - Phone
- (312) 926-2000
Quick Facts
- NPI
- 1639750532
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile